Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO

Core Viewpoint - Novo Nordisk A/S faced a significant drop in stock price following the announcement of disappointing results from their "REDEFINE 1" trial, which investigated the efficacy of CagriSema for weight loss [1] Summary by Relevant Sections Class Action Notice - Shareholders who purchased shares of Novo Nordisk (NVO) between November 2, 2022, and December 19, 2024, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment [1] - The class action is in response to allegations stemming from the trial results announced on December 20, 2024 [1] Trial Results - The "REDEFINE 1" trial showed that patients treated with CagriSema experienced a weight loss of 22.7% after 68 weeks, which was below the company's target of at least 25% [1] - Only 57.3% of patients were on the highest dosage during the trial, as they were allowed to modify their own dosage [1] Stock Price Impact - Following the announcement of the trial results, Novo's stock price fell by $18.44 per share, closing at $85.00 per share [1]